Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) completed its business combination in 2021 through a merger with Arya Sciences Acquisition Corp III, a blank-check company sponsored by Perceptive Advisors. The combined company operates in the life sciences sector, focused on developing a single-molecule proteomics platform designed to enable large-scale protein analysis at unprecedented scale and resolution. As a post-merger public company, Nautilus continues to advance its proprietary technology toward commercial readiness and filed a quarterly report on Form 10-Q with the SEC on April 28, 2026. Investors and analysts seeking comprehensive deal history, SEC filings, and company-level metrics for NAUT and thousands of other de-SPAC companies can access the full dataset by signing up at SpacDesk.